CA-JSR-LIFE-SCIENCES
JSR Life Sciences, LLC (JSR) today announced that Mark W. Womack will serve as the Chief Executive Officer of two of its affiliate companies: KBI Biopharma , a leading global CDMO specializing in drug development and biologics manufacturing, and Selexis SA , an industry-leading cell line development provider. Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the U.S. Womack’s appointment is effective May 2, 2022. He will report to JSR Life Sciences President Tim Lowery.
“Mark’s impressive track record includes extensive CDMO and biologics experience, as well as the ability to deliver overall growth, revenue generation, and organizational alignment,” said Tim Lowery, President, JSR Life Sciences . “His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees. I look forward to working with Mark and his teams as we continue to provide best-in-class capabilities for outsourced drug development and manufacturing services.”
Womack brings a consistent track record of successful leadership and life sciences experience to KBI and Selexis. He most recently served as the CEO and Managing Director of Stelis Biopharma, where he oversaw the development and implementation of the infrastructure for a pure-play CDMO, including an end-to-end biologics offering, across multiple facilities. In 2021, he led the company’s efforts to build and qualify a state-of-the-art vaccine facility capable of clinical and commercial-scale manufacturing in record time.
Prior to Stelis, Womack served as the Chief Business Officer at AGC Biologics, in which his extensive experience driving organizational performance improvements led to a nearly 300% increase in new sales in just two years. His career began with more than ten years of distinguished service in the U.S. Navy, where he was recognized with many of their highest honors for exceptional leadership.
“KBI and Selexis are helping create a world where everyone has access to vital treatments that improve or extend their lives,” said Womack. “I’m honored to join JSR and these two great organizations in their mission to help our clients solve their greatest scientific challenges – in turn, providing life-saving therapeutics to patients across the globe. I look forward to supporting the KBI and Selexis teams’ continued growth trajectory and building on their long commitment to quality and innovation.”
Womack joins KBI and Selexis amid a period of profound expansion for both companies. In April, KBI cut the ribbon on its new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. This will soon be followed by significant European expansion through the opening of a newly scaled, state-of-the-art GMP facility that will co-locate both KBI Biopharma and Selexis SA in Geneva, Switzerland .
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com
About KBI Biopharma
KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com .
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 155 drug candidates in preclinical and clinical development and the manufacture of nine commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer20.1.2026 13:00:00 CET | Press release
Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Symposium Agendia, Inc., a leader in precision oncology for breast cancer, today announced that the updated NCCN Clinical Practice Guidelines in Oncology1 (NCCN Guidelines®) now recognize that MammaPrint® + BluePrint® can help identify a subset of hormone receptor positive, HER2-negative (HR+/HER2–) early-stage breast cancer (EBC) patients most likely to benefit from anthracycline-based chemotherapy. “I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal investigator for the FLEX Study. “I think the biologic rationale and the data underpinning the observation that High Risk 2 Luminal (by BluePrint) breast cancer patients benefit from anthracycline therapy are quite strong.” The updated NCCN Guidelines are based on a three-year analysis of outcomes
Cargill Wins 2026 BIG Innovation Award20.1.2026 13:00:00 CET | Press release
The company was honored as a Top Innovator for large-scale AI-and-data-driven innovation advancing food security, operational excellence and resilient food systems Cargill today announced it has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. Cargill was honored in the Innovative Organizations category, alongside a cohort of 159 companies, products and leaders that are transforming industries through applied innovation and measurable real-world impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120109897/en/ Cargill has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agr
Armis Helps Italian Grocery Retailer Multicedi Strengthen Cyber Resilience20.1.2026 13:00:00 CET | Press release
Armis Centrix™ identified that 10-15% of connected assets across the organization’s network were previously unaccounted for, introducing cyber risk Armis, the cyber exposure management & security company, today announced that Multicedi, one of the leading grocery retail groups in Central and Southern Italy, is using Armis Centrix™, Armis’ Cyber Exposure Management Platform, to strengthen its cybersecurity posture. “Before introducing Armis, critical issues were addressed only when malfunctions or abnormal events had already occurred,” said Livio De Prisco, Director of Information Systems at Multicedi. “With Armis Centrix™, the approach has completely changed: rather than responding reactively, the company now has a real-time view of its entire device fleet and can manage it proactively. We can detect devices that have been added to the network, prioritize risks based on their criticality, and define action plans and budgets consistent with our operational and regulatory requirements.”
TreviPay Launches Pay by Invoice for Issuers Enabled by Visa Credentials20.1.2026 13:00:00 CET | Press release
TreviPay’s Pay by Invoice solution enables Visa issuers and their business buyers to use Visa credentials for supplier payments to unlock new B2B opportunities TreviPay announces the launch of its Pay by Invoice solution for Visa-issuing banks, enabling issuers to capture a greater share of the $58 trillion North American B2B payments market. Through this collaboration with Visa, a world leader in digital payments, TreviPay’s order-to-cash automation technology combines with Visa’s commercial payment capabilities to help issuers move fragmented B2B spend into strategic, issuer-financed, invoice-based transactions. A Murphy Research study, found 26% of corporate payments are still made with checks or rely on manual legacy ACH processes. The study also shows 78% of global B2B buyers need customization or control in their payments and invoicing workflows, with 61% preferring to pay on net terms. Pay by Invoice helps banks meet these expectations by providing suppliers with early payment (
Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI20.1.2026 11:03:00 CET | Press release
The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE: PM) today released a new white paper, “Human Cognition: The Next Frontier?”, inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the “superskill” of the future, driving progress in an era of human-machine collaboration. As AI automates routine tasks and augments knowledge work, PMI argues that nurturing and protecting cognitive capacity will be essential for organizations seeking to remain resilient and relevant. Where once technology often automated labor-intensive jobs in the quest to improve productivity, now, as intelligent systems take on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom